Capricor Therapeutics (NASDAQ:CAPR) dosed the first two patients in its Phase 2 trial evaluating CAP-1002 for the treatment of severe COVID-19.
CAP-1002 is an intravenously delivered allogeneic cardiac cell therapy designed to modulate COVID-19-associated cytokine storm.
The trial will enroll 60 patients who have been diagnosed with SARS-CoV-2 and require supplemental oxygen. The study’s primary objectives are to determine the safety and effectiveness of intravenously infused CAP-1002 for improving clinical outcomes in severe-to-critical COVID-19 patients.
“As hospitalizations continue to increase, we have a therapeutic under investigation for patients at a high-risk for significant morbidity or even death,” Linda Marbán, Capricor’s CEO, said in a statement.
“It is important to remember that many patients are suffering from long term cardiac consequences from COVID-19. As CAP-1002 directly targets cardiac dysfunction, CAP-1002 potentially may also be an important tool in the treatment of the cardiac complications of COVID-19,” she added.
